His clinical expertise is in the treatment of patients with leukemia. Dr. Gill studies how genetically modified T cells can be used to treat blood cancers and has recently expanded his interests in the use of genetically modified T cells beyond cancer into other difficult to treat diseases such as neurodegenerative disorders. He obtained his medical degree and his doctorate from the University of Melbourne in Australia. He specialized in malignant hematology at the Peter MacCallum Cancer Centre in Melbourne and then completed post-doctoral training in blood and marrow transplantation (BMT) research at Stanford University.